1,2-diaza-(Z)-1-cyclooctene | 29852-58-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1,2-diaza-(Z)-1-cyclooctene
• 英文别名: (Z)-1,2-diazacyclooct-1-ene；cis-1,2-Diaza-1-cycloocten；1,2-Diaza-(Z)-1-cycloocten；1,2-Diaza-1-cycloocten；3,4,5,6,7,8-hexahydro-[1,2]diazocine
• CAS: 29852-58-2
• 化学式: C₆H₁₂N₂
• 分子量: 112.175
• InChiKey: UHPDPQPPEHSQRR-FPLPWBNLSA-N

物化性质

• 沸点：
  146.8±7.0 °C(Predicted)
• 密度：
  1.02±0.1 g/cm3(Predicted)

反应信息

• 作为反应物：
  描述：

  1,2-diaza-(Z)-1-cyclooctene 反应 10.0h， 以60%的产率得到1,2-diaza-(E)-1-cyclooctene
  参考文献：
  名称：

  Photochemical isomerization of eight-membered cyclic azo compounds

  摘要：

  DOI：

  10.1021/jo00315a015
• 作为产物：
  描述：

  1,2-bis(ethoxycarbonyl)-1,2-diazacyclooctane 生成 1,2-diaza-(Z)-1-cyclooctene
  参考文献：
  名称：

  Adam, Waldemar; Oppenlaender, Thomas, Canadian Journal of Chemistry, 1985, vol. 63, p. 1829 - 1832

  摘要：

  DOI：

文献信息

• [EN] SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH<br/>[FR] DÉRIVÉS DE SPIROQUINOXALINE EN TANT QU'INHIBITEURS DE LA MORT CELLULAIRE RÉGULÉE NON APOPTOTIQUE
  申请人：HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT GMBH

  公开号：WO2015007730A1

  公开（公告）日：2015-01-22

  The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

  本发明涉及抑制非凋亡调节细胞死亡的化合物，以及包含这些化合物的制药组合物。此外，本发明还涉及这些化合物和制药组合物在治疗中的应用，特别是在治疗由非凋亡调节细胞死亡特征化的疾病、疾病或疾病中，或者在非凋亡调节细胞死亡可能发挥或发挥重要作用的情况下。本文描述的化合物和制药组合物还可用于治疗由氧化应激特征化的疾病、疾病或疾病，或者氧化应激可能发挥或发挥重要作用的情况；和/或由（1）一个或多个死亡体受体的成分；（2）死亡结构域受体；和/或（3）Toll样受体的激活；和/或（4）铁死亡/铁死亡信号通路中的参与者的特征化，或者激活（1）至（3）和/或（4）中的任何一个可能发挥或发挥重要作用的情况。
• MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID
  申请人：Genomatica, Inc.

  公开号：US20130303723A1

  公开（公告）日：2013-11-14

  The invention provides a non-naturally occurring microbial organism having a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway. The invention additionally provides a method for producing 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid. The method can include culturing a 6-aminocaproic acid, caprolactam or hexametheylenediamine producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding a 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce 6-aminocaproic acid, caprolactam, hexametheylenediamine or levulinic acid.

  本发明提供了一种非自然存在的微生物生物体，具有6-氨基己酸、己内酰胺、六亚甲基二胺或丙酮酸途径。该微生物生物体含有至少一种外源核酸，编码相应的6-氨基己酸、己内酰胺、六亚甲基二胺或丙酮酸途径中的酶。此外，本发明还提供了一种生产6-氨基己酸、己内酰胺、六亚甲基二胺或丙酮酸的方法。该方法可以包括培养生产6-氨基己酸、己内酰胺或六亚甲基二胺的微生物生物体，在条件和足够的时间内，微生物生物体表达至少一种外源核酸编码的6-氨基己酸、己内酰胺、六亚甲基二胺或丙酮酸途径酶，以产生相应的产物。
• Agent for treating metallic surface, surface-treated metal material and coated metal material
  申请人：Toyo Boseki Kabushiki Kaisha

  公开号：EP0952193A1

  公开（公告）日：1999-10-27

  A chromium-free agent for treating metallic surface comprising the following (i)-(iv): (i) at least one of (A) a mixture of an aluminum salt and an inorganic oxide particle and (B) an aluminum-containing inorganic oxide particle comprising aluminum, oxygen and at least one element other than these two (ii) a salt of a metal other than aluminum (iii) a phosphorus compound (iv) a resin and/or a precursor thereof provided that when (i) is a mixture of an aluminum salt and an inorganic oxide particle, the equivalent ratio of phosphorus/aluminum is not less than 0.1. The agent for treating metallic surface is applied to the surface of a metal material such as steel plate, plated steel plate, alloy-plated steel plate, alloy plate, silicon steel plate, stainless steel plate,    shape steel, pipe, wire material and the like, and dried to form a film superior in corrosion resistance, adhesion to a metal material and adhesion to a paint. The present invention further relates to a metal material which has been subjected to a surface treatment with said agent for treating metallic surface, and to a metal material obtained by applying a resin to said metal material.

  一种用于处理金属表面的无铬剂，包括以下(i)-(iv)项： (i) (A)铝盐和无机氧化物粒子的混合物和(B)含铝无机氧化物粒子中的至少一种，该无机氧化物粒子包括铝、氧和除这两种元素之外的至少一种元素 (ii) 铝以外的一种金属盐 (iii) 磷化合物 (iv) 树脂和/或其前体，条件是当(i)是铝盐和无机氧化物颗粒的混合物时，磷/铝的当量比不小于 0.1。 金属表面处理剂适用于金属材料表面，如钢板、镀层钢板、合金镀层钢板、合金板、硅钢板、不锈钢板、 形钢、管材、线材等金属材料的表面，干燥后形成一层耐腐蚀性、与金属材料的附着力和与涂料的附着力均优越的薄膜。本发明还涉及使用上述金属表面处理剂进行表面处理的金属材料，以及通过在上述金属材料上涂敷树脂而获得的金属材料。
• 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY
  申请人：Xiamen Sinopeg Biotech Co., Ltd.

  公开号：EP3315531A1

  公开（公告）日：2018-05-02

  Disclosed are an 8-arm polyethylene glycol (PEG) derivative (formula 1), manufacturing method and modified bio-related substance thereby, wherein a tetravalent group U and four trivalent groups Ec form a highly symmetric octavalent central structure CORE0 together, Lc connects the octavalent center to eight PEG arms having polydiversity or monodiversity and having n1-n8 as the degrees of polymerization thereof. The terminal of one PEG chain is connected to at least one functional group F (k ≥ 1), and said PEG chain and F can be directly connected (g = 0) or connected with a divalent linking group L0 connected with a terminal branched group G (g = 1) therebetween. The latter provides more reacting sites to combine more pharmaceutical molecules, thereby increasing the drug loading capacity. The near-center symmetric structure of the derivative allows more precise control over the molecular weight during large-scale production, thereby facilitating acquisition of a product having a narrower molecular weight distribution. A bio-related substance modified thereby has a more uniform and controllable performance.

  本发明公开了一种 8 臂聚乙二醇（PEG）衍生物（式 1）、其制造方法和改性生物相关物质，其中一个四价基团 U 和四个三价基团 Ec 共同形成一个高度对称的八价中心结构 CORE0，Lc 将八价中心连接到八个 PEG 臂上，这些 PEG 臂具有多元性或单元性，其聚合度为 n1-n8。一条 PEG 链的末端与至少一个官能团 F（k ≥ 1）相连，所述 PEG 链和 F 可以直接相连（g = 0），也可以通过二价连接基 L0 与中间的末端支化基 G（g = 1）相连。后者提供了更多的反应位点，可以结合更多的药物分子，从而提高药物负载能力。衍生物的近中心对称结构可以在大规模生产过程中更精确地控制分子量，从而有利于获得分子量分布更窄的产品。由此改性的生物相关物质具有更均匀、更可控的性能。
• Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
  申请人：Helmholtz Zentrum Munchen—Deutches Forschungszentrum Fur Gesundheit und Umwelt

  公开号：US10280179B2

  公开（公告）日：2019-05-07

  The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterized by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterized by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterized by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

  本发明涉及作为非凋亡调节细胞死亡抑制剂的化合物，以及含有此类化合物的药物组合物。此外，本发明还涉及此类化合物和药物组合物在治疗中的用途，特别是在治疗以非凋亡调节性细胞死亡为特征或非凋亡调节性细胞死亡可能起或起重要作用的病症、紊乱或疾病中的用途。本文所述的化合物和药物组合物还可用于治疗以氧化应激为特征的病症、紊乱或疾病，或氧化应激可能起作用或起重要作用的病症、紊乱或疾病；和/或以（1）坏死体的一种或多种成分；（2）死亡结构域受体；和/或（3）Toll 样受体；和/或（4）铁凋亡/铁变态反应信号的激活为特征的病症、紊乱或疾病，或（1）至（3）和/或（4）中的任何一种激活可能起或起重要作用的病症、紊乱或疾病。